All articles by mrinmoyee hazarika

mrinmoyee hazarika

BioCryst gains marketing authorisation for Orladeyo in Chile

The safety and effectiveness of the drug prophylaxis for acute HAE attacks are yet to be proved.

UK to provide up to £39m for AMR research

Up to £24m will be used to strengthen the UK’s collaboration with CARB-X.

EMA validates Sobi’s marketing authorisation application for efanesoctocog alfa

Efanesoctocog alfa is a FVIII therapy that has been developed to treat haemophilia A.

FDA accepts resubmission of Ardelyx’s NDA for XPHOZAH

The resubmitted NDA is based on a comprehensive development programme that includes three Phase III trials of XPHOZAH.

LAPIX receives US patent for LPX-TI641 to treat autoimmune diseases

LPX-TI641 is being developed to treat neuro-autoimmune indications including multiple sclerosis.

Elevar submits new drug application for uHCC combo therapy

Rivoceranib is an oral TKI, while camrelizumab is a PD-1 inhibitor.

AGC Biologics rolls out new viral vector platforms

A group of scientists designed BravoAAV and ProntoLVV at AGC Biologics’ site in Milan, Italy.

MIF invests in Nectin to investigate multiple myeloma drug candidate

NTX1088 is Nectin’s lead immunotherapy drug candidate that targets a major immune checkpoint, PVR, also called CD155.

Scribe and Prevail partner for CRISPR-based genetic medicines

Under the deal, Prevail obtains exclusive rights to use Scribe’s CRISPR X-Editing technologies to develop the medicines.

Juno Pharmaceuticals buys Omega Laboratories

The merged entity represents one of the biggest specialist generic injectable operations in Canada.